Dato-Dxd Shows Survival Improvements in HR+/HER2– Breast Cancer
The dual primary end points of overall survival and progression-free survival were encouraging when patients with hormone receptor–positive (HR+), HER2-negative (HER2–) breast cancer were treated with datopotamab deruxtecan.